Monod Bio
| Startup company | |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | |
| Founders 👔 | Daniel Adriano Silva Manzano, David Shoultz, Alfredo Quijano Rubio, David Baker |
| Headquarters 🏙️ | , Seattle, Washington , |
Area served 🗺️ | |
Key people | Daniel Adriano Silva Manzano (CEO), David Shoultz (COO), Alfredo Quijano Rubio (CSO) |
| Members | |
Number of employees | |
| 🌐 Website | monod.bio |
| 📇 Address | |
| 📞 telephone | |
Monod Bio is an American biotechnology company based in Seattle, Washington. The company is developing novel clinical diagnostics and biotechnology tools using AI-powered de novo protein design.[1]
History
The company was founded by Daniel Adriano Silva Manzano, David Shoultz, and Alfredo Quijano Rubio as a spin-out from the University of Washington Institute for Protein Design and the lab of Dr. David Baker.[1] Dr. Baker is a co-founder and close advisor.[1]
It was originally housed in the CoMotion Labs biotech incubator at University of Washington before relocating to a separate facility in South Lake Union.[2][1] In 2022, Monod Bio completed a seed round financing of $25 million dollars with Matrix Capital Management as a lead investor and participation from the Global Health Investment Corporation Cerano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures.[1][3][4][5]
In August 2023, Alfredo Quijano Rubio received Health and Business Insider's 30 under 40 award for his work with the company.[6]
Research
Monod Bio utilizes the "Rosetta" protein engineering software developed at the Institute for Protein Design to develop biosensors.[1] These sensors emit bioluminescent signals in the presence of an analyte, which was showcased in a Nature publication in 2021.[7] The two-protein (known as lucCage and lucKey), modular system emits light when the proteins bind, causing an attached luciferase to emit light.[7]
In December 2022, the lucCage-lucKey biosensor system was featured in a new article in Advanced Materials, where the Baker Lab—featuring CSO, Alfredo Quijano Rubio—collaborated with the Silk Lab at Tufts University.[8] This collaboration theorized the incorporation of the biosensors into silk fibers, allowing for detection of proteins upon contact with the fibers.[8] In February 2023, Monod Bio announced a publication in Nature introducing its de novo protein design platform for the creation of its novel luciferase, LuxSit.[9][10]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Schubert, Charlotte (15 August 2022). "Institute for Protein Design spinout Monod Bio raises $25M for molecular biosensors". GeekWire. Retrieved 7 December 2023.
- ↑ Schubert, Charlotte (2 August 2023). "Seattle startups move into growing science cluster in South Lake Union". GeekWire. Retrieved 7 December 2023.
- ↑ Gormley, Brian (15 August 2022). "Biotech Startup Monod Bio Collects $25 Million Seed Financing". Wall Street Journal Venture Capital. Retrieved 7 December 2023.
- ↑ Pratap, Aayushi (15 August 2022). "David Baker lab spinout scores seed funding to build a biosensor from engineered protein". Endpoints News. Retrieved 7 December 2023.
- ↑ Vedantam, Keerthi (15 August 2022). "Monod Bio Raises $25M To Quickly Diagnose Diseases". Crunchbase News. Retrieved 7 December 2023.
- ↑ Brueck, Hilary (17 August 2023). "30 Leaders Under 40 Changing Healthcare in 2023". Axel Springer SE. Business Insider. Retrieved 7 December 2023.
- ↑ 7.0 7.1 Quijano-Rubio, Alfredo (27 January 2021). "De novo design of modular and tunable protein biosensors". Nature. 591 (7850): 482–487. doi:10.1038/s41586-021-03258-z. PMC 8074680 Check
|pmc=value (help). PMID 33503651 Check|pmid=value (help). - ↑ 8.0 8.1 d'Amone, Luciana; Matzeu, Guisy; Quijano-Rubio, Alfredo; Callahan, Gregory; Napier, Bradley; Baker, David; Omenetto, Fiorenzo (9 December 2022). "Reshaping de Novo Protein Switches into Bioresponsive Materials for Biomarker, Toxin, and Viral Detection". Advanced Materials. 35 (11). doi:10.1002/adma.202208556. Retrieved 20 December 2023.
- ↑ Ha, Kimberely (22 February 2023). "Monod Bio Announces Publication in Nature Highlighting De Novo Protein Technology Platform for the Creation of Novel Luciferases". Berkshire Hathaway. Business Wire. Retrieved 7 December 2023.
- ↑ Yeh, Andy (22 February 2023). "De novo design of luciferases using deep learning". Nature. 614 (7949): 774–780. doi:10.1038/s41586-023-05696-3. PMC 9946828 Check
|pmc=value (help). PMID 36813896 Check|pmid=value (help).
This article "Monod Bio" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Monod Bio. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
